GHCM
ALDR

Glen Harbor Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Glen Harbor Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,032
Closed -$200K – 1363
2018
Q3 		$200K Buy
12,032
+7,088
+143% +$128K ﹤0.01% 1050
2018
Q2 		$78K Buy
4,944
+464
+10% +$7.05K ﹤0.01% 1173
2018
Q1 		$57K Buy
+4,480
New +$64.8K ﹤0.01% 1218

Other funds holding ALDR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Glen Harbor Capital Management's ALDR Position: Q4 2018 in Review

Glen Harbor Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 12,032 shares — an estimated $200K sold.

Glen Harbor Capital Management first reported a position in ALDR in Q1 2018 and held it in 3 quarters. The position peaked at $200K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

  • Glen Harbor Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Glen Harbor Capital Management sold 12,032 Alder Biopharmaceuticals shares in Q4 2018, an estimated $200K.
  • Glen Harbor Capital Management first reported a position in Alder Biopharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Glen Harbor Capital Management's Alder Biopharmaceuticals position peaked at $200K in Q3 2018.
  • 124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Glen Harbor Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.